Beyond Air® Secures Up to $32 Million to Accelerate Growth
Beyond Air (NASDAQ: XAIR) entered financing agreements with Streeterville Capital providing up to $32 million in potential proceeds: a $12 million promissory note and a $20 million equity line of credit (ELOC). Pro forma cash, cash equivalents, restricted cash and marketable securities totaled $22.9 million as of September 30, 2025, which includes the $12 million note. The promissory note bears 15% annual interest, matures in 24 months with no payments for the first 12 months, and places $6 million in a restricted account. The ELOC allows sale of up to $20 million of common stock over 24 months and requires an S-1 resale registration. Management says the financing extends runway into calendar 2027 and supports LungFit PH commercial expansion and a planned second-generation launch before end of 2026.
Beyond Air (NASDAQ: XAIR) ha stipulato accordi di finanziamento con Streeterville Capital che prevedono potenziali proventi fino a $32 milioni: una $12 milioni nota promissoria e una $20 milioni linea di credito per capitale azionario (ELOC). Il flusso di cassa pro forma, le disponibilità liquide, la liquidità ristretta e i titoli negoziabili totali ammontano a $22,9 milioni al 30 settembre 2025, che include la nota da $12 milioni. La nota promissoria comporta un interesse annuo del 15%, scadenza a 24 mesi con nessun pagamento nei primi 12 mesi, e convoglia $6 milioni in un conto riservato. L’ELOC consente la vendita di fino a $20 milioni di azioni ordinarie in 24 mesi e richiede una registrazione di rivendita S-1. La direzione afferma che il finanziamento estende la runway fino al calendario 2027 e sostiene l’espansione commerciale di LungFit PH e un lancio di seconda generazione previsto entro la fine del 2026.
Beyond Air (NASDAQ: XAIR) firmó acuerdos de financiación con Streeterville Capital que contemplan hasta $32 millones en ingresos potenciales: una nota promissoria de $12 millones y una línea de crédito de capital contable (ELOC) de $20 millones. El efectivo pro forma, equivalentes de efectivo, efectivo restringido y valores negociables totalizaron $22.9 millones al 30 de septiembre de 2025, lo que incluye la nota de $12 millones. La nota promissoria tiene un interés anual del 15%, vence en 24 meses sin pagos durante los primeros 12 meses, y coloca $6 millones en una cuenta restringida. La ELOC permite la venta de hasta $20 millones de acciones comunes en 24 meses y requiere un registro de reventa S-1. La dirección dice que el financiamiento extiende la runway hacia el calendario 2027 y respalda la expansión comercial de LungFit PH y un lanzamiento de segunda generación previsto antes de finalizar el 2026.
Beyond Air (NASDAQ: XAIR)가 Streeterville Capital과 자금 조달 계약을 체결하여 최대 $32 백만의 잠재 수익을 제공합니다: $12 백만의 차입 어음과 $20 백만의 주식 현금화 신용한도(ELOC). 프로 포마 현금, 현금 등가물, 제한 현금 및 매매 가능 증권의 총액은 2025년 9월 30일 기준 $22.9 백만이며, 이는 $12 백만의 어음을 포함합니다. 차입 어음은 연이자 15%를 가지며 24개월 만기이고 최초 12개월 동안은 상환이 없으며 $6 백만을 제한 계좌에 예치합니다. ELOC는 24개월 동안 최대 $20 백만의 보통주 매도를 허용하고 S-1 재판매 등록을 요구합니다. 경영진은 이 자금 조달로 운영 기간(runway)이 2027년 달력까지 연장되고 LungFit PH의 상용화 확장과 2026년 말 이전의 2세대 출시를 뒷받침한다고 말합니다.
Beyond Air (NASDAQ: XAIR) a conclu des accords de financement avec Streeterville Capital offrant jusqu’à $32 millions de produits potentiels: une note promissoire de $12 millions et une ligne de crédit sur valeurs mobilières (ELOC) de $20 millions. La trésorerie pro forma, les équivalents de trésorerie, la trésorerie restreinte et les valeurs mobilières négociables s’élèvent à $22,9 millions au 30 septembre 2025, ce qui inclut la note de $12 millions. La note promissoire porte un intérêt annuel de 15%, arrive à échéance en 24 mois avec aucun paiement au cours des 12 premiers mois, et place $6 millions dans un compte restreint. L’ELOC permet la vente de jusqu’à $20 millions d’actions ordinaires sur 24 mois et nécessite une inscription de revente S-1. La direction indique que le financement prolonge la marge de manœuvre jusqu’au calendrier 2027 et soutient l’expansion commerciale de LungFit PH et un lancement de seconde génération prévu avant la fin du 2026.
Beyond Air (NASDAQ: XAIR) hat Finanzierungsvereinbarungen mit Streeterville Capital getroffen, die potenziell bis zu $32 Millionen an Erlösen ermöglichen: eine $12 Millionen Wechselnote und eine $20 Millionen Aktienkreditlinie (ELOC). Pro-Forma-Kasse, liquide Mittel, eingeschränktes Bargeld und handelbare Wertpapiere beliefen sich zum 30. September 2025 auf insgesamt $22,9 Millionen, einschließlich der $12 Millionen Note. Die Wechselnote trägt einen jährlichen Zinssatz von 15%, läuft in 24 Monaten fällig und sieht in den ersten 12 Monaten keine Zahlungen vor; außerdem werden $6 Millionen auf ein eingeschränktes Konto eingezahlt. Die ELOC erlaubt den Verkauf von bis zu $20 Millionen an Stammaktien über 24 Monate und erfordert eine S-1-Verkaufsregistrierung. Das Management sagt, dass die Finanzierung die Runway bis in das Kalenderjahr 2027 verlängert und die kommerzielle Expansion von LungFit PH sowie einen geplanten zweiten Generationsstart vor Ende 2026 unterstützt.
Beyond Air (NASDAQ: XAIR) أبرمت اتفاقيات تمويل مع Streeterville Capital تتيح عوائد محتملة تصل إلى $32 مليون: سند وعد ب($12 مليون) ونطاق ائتماني للأسهم (ELOC) قدره $20 مليون. بلغت السيولة النقدية و الموجودات النقدية المقيَّدة والأوراق المالية القابلة للتداول مجتمعةً $22.9 مليون حتى 30 سبتمبر 2025، وهو ما يشمل السند $12 مليون. يحمل سند الوعد فائدة سنوية قدرها 15%، ويستحق خلال 24 شهراً مع عدم وجود دفعات خلال الأشهر الـ12 الأولى، ويوضع $6 مليون في حساب مقيد. يسمح ELOC ببيع حتى $20 مليون من الأسهم العادية خلال 24 شهراً ويتطلب تسجيل إعادة بيع من النوع S-1. تقول الإدارة إن التمويل يمد عمر الشركة حتى تقويم 2027 ويدعم التوسع التجاري لـ LungFit PH وإطلاق الجيل الثاني المخطط قبل نهاية 2026.
- Up to $32M total financing available
- Pro forma cash of $22.9M as of Sep 30, 2025
- Financing extends cash runway into calendar 2027
- $20M ELOC provides flexible access to equity capital over 24 months
- Promissory note carries a high 15% annual interest rate
- ELOC could cause meaningful equity dilution if fully drawn
- $6M of note proceeds placed in a restricted account
Insights
Financing extends runway to
Beyond Air secures up to
The promissory note carries a
Key dependencies and risks include achieving the company’s revenue projections for LungFit PH, the planned launch of a second‑generation LungFit PH prior to the end of
Enters agreements for a
Proforma cash, cash equivalents, restricted cash and marketable securities of
Extends cash runway into calendar 2027
GARDEN CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it has entered into financing agreements with Streeterville Capital, providing up to
“This strategic cash infusion provides flexibility to accelerate our commercial expansion, aimed at driving sales growth for LungFit PH,” said Steve Lisi, Chairman and Chief Executive Officer. “Based on current projections for LungFit PH global revenues and the anticipated launch of our second generation LungFit PH prior to the end of calendar 2026, we believe this financing positions us to potentially achieve profitability.”
Under the terms of the agreement, Beyond Air issued a
In addition, the Company entered into a
Brookline Capital Markets, a division of Arcadia Securities, LLC, and H.C. Wainwright & Co., LLC acted as co-financial advisors.
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
About LungFit *
Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.
LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
*Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
What financing did Beyond Air (XAIR) secure on November 5, 2025?
How does the $12M promissory note to Streeterville Capital affect Beyond Air (XAIR)?
What is the size and term of the ELOC for Beyond Air (XAIR)?
How much cash did Beyond Air (XAIR) report pro forma as of September 30, 2025?
What impact does the financing have on Beyond Air's (XAIR) runway and product plans?
